Merck’s Lab Closure Harms Japan’s Drug-Making Goals – Japanese Cabinet Official
This article was originally published in PharmAsia News
A Japanese official said U.S.-based Merck's decision to close its research laboratory in Japan is a blow to the government's effort to make the country one of the world's largest drug makers. Merck, Pfizer, Novartis AG and GlaxoSmithKline have closed labs recently, in most cases moving them to other Asian nations. Kiyoshi Kurokawa, the Cabinet's policy adviser, said the government plan to double drug production and attract foreign makers will be hampered by the closings. Japan's goal is to be developer of a quarter of the world's new drugs. (Click here for more
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.